Literature DB >> 10369464

Comparison of the effects of [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)NH2 in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin receptors.

H Okawa1, B Nicol, R Bigoni, R A Hirst, G Calo, R Guerrini, D J Rowbotham, D Smart, A T McKnight, D G Lambert.   

Abstract

Nociceptin(NC) is the endogenous ligand for the opioid receptor like-1 receptor (NC-receptor). [Phe1(psi)(CH2-NH)Gly2]Nociceptin(1-13)NH2 ([F/G]NC(1-13)NH2) has been reported to antagonize NC actions in peripheral guinea-pig and mouse tissues. In this study, we investigated the effects of a range of NC C-terminal truncated fragments and [F/G]NC(1-13)NH2 on NC receptor binding, glutamate release from rat cerebrocortical slices (rCX), inhibition of cyclic AMP accumulation in CHO cells expressing the NC receptor (CHO(NCR)) and electrically evoked contractions of the rat vas deferens (rVD). In radioligand binding assays, a range of ligands inhibited [125I]-Tyr14-NC binding in membranes from rCX and CHO(NCR) cells. As the peptide was truncated there was a general decline in pKi. [F/G]NC(1-13)NH2 was as potent as NC(1-13)NH2. The order of potency for NC fragments to inhibit cyclic AMP accumulation in whole CHO(NCR) cells was NCNH2> or =NC=NC(1-13)NH2>NC(1-12)NH2> >NC(1-11)NH2. [F/G]NC(1-13)NH2 was a full agonist with a pEC50 value of 8.65. NCNH2 and [F/G]NC(1-13)NH2 both inhibited K+ evoked glutamate release from rCX with pEC50 and maximum inhibition of 8.16, 48.5+/-4.9% and 7.39, 58.9+/-6.8% respectively. In rVD NC inhibited electrically evoked contractions with a pEC50 of 6.63. Although [F/G]NC(1-13)NH2, displayed a small (instrinsic activity alpha = 0.19) but consistent residual agonist activity, it acted as a competitive antagonist (pA2 6.76) in the rVD. The differences between [F/G]NC(1-13)NH2 action on central and peripheral NC signalling could be explained if [F/G]NC(1-13)NH2 was a partial agonist with high strength of coupling in the CNS and low in the periphery. An alternative explanation could be the existence of central and peripheral receptor isoforms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10369464      PMCID: PMC1566005          DOI: 10.1038/sj.bjp.0702539

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  Nociceptin inhibits T-type Ca2+ channel current in rat sensory neurons by a G-protein-independent mechanism.

Authors:  F A Abdulla; P A Smith
Journal:  J Neurosci       Date:  1997-11-15       Impact factor: 6.167

Review 2.  The orphanin FQ system: an emerging target for the management of pain?

Authors:  T Darland; D K Grandy
Journal:  Br J Anaesth       Date:  1998-07       Impact factor: 9.166

3.  Relationship between binding affinity and functional activity of nociceptin/orphanin FQ.

Authors:  I D Adapa; L Toll
Journal:  Neuropeptides       Date:  1997-10       Impact factor: 3.286

4.  A new selective antagonist of the nociceptin receptor.

Authors:  R Guerrini; G Calo; A Rizzi; R Bigoni; C Bianchi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  1998-01       Impact factor: 8.739

5.  Distribution of nociceptin/orphanin FQ receptor transcript in human central nervous system and immune cells.

Authors:  J Peluso; K S LaForge; H W Matthes; M J Kreek; B L Kieffer; C Gavériaux-Ruff
Journal:  J Neuroimmunol       Date:  1998-01       Impact factor: 3.478

6.  Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist.

Authors:  G Calo'; R Guerrini; R Bigoni; A Rizzi; C Bianchi; D Regoli; S Salvadori
Journal:  J Med Chem       Date:  1998-08-27       Impact factor: 7.446

7.  Rat central ORL-1 receptor uncouples from adenylyl cyclase during membrane preparation.

Authors:  H Okawa; R A Hirst; D Smart; A T McKnight; D G Lambert
Journal:  Neurosci Lett       Date:  1998-04-17       Impact factor: 3.046

8.  [Phe1psi(CH2-NH)Gly2]-nociceptin-(1-13)NH2, a proposed antagonist of the nociceptin receptor, is a potent and stable agonist in the rat spinal cord.

Authors:  I S Xu; Z Wiesenfeld-Hallin; X J Xu
Journal:  Neurosci Lett       Date:  1998-06-19       Impact factor: 3.046

9.  Pharmacological studies on the "orphan" opioid receptor in central and peripheral sites.

Authors:  J R Nicholson; S J Paterson; J R Menzies; A D Corbett; A T McKnight
Journal:  Can J Physiol Pharmacol       Date:  1998-03       Impact factor: 2.273

10.  [Phe1psi(CH2-NH)Gly2]nociceptin-(1-13)-NH2 is an agonist of the nociceptin (ORL1) receptor.

Authors:  J L Butour; C Moisand; C Mollereau; J C Meunier
Journal:  Eur J Pharmacol       Date:  1998-05-15       Impact factor: 4.432

View more
  19 in total

1.  Effects of nociceptin and endomorphin 1 on the electrically stimulated human vas deferens.

Authors:  R Bigoni; G Calo; R Guerrini; J W Strupish; D J Rowbotham; D G Lambert
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

2.  Characterization of the ORL(1) receptor on adrenergic nerves in the rat anococcygeus muscle.

Authors:  M Ho; A D Corbett; A T McKnight
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

3.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 4.  Pharmacology of nociceptin and its receptor: a novel therapeutic target.

Authors:  G Calo'; R Guerrini; A Rizzi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

5.  Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin.

Authors:  S Sbrenna; M Marti; M Morari; G Calo'; R Guerrini; L Beani; C Bianchi
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

6.  Nociceptin, Phe(1)psi-nociceptin(1 - 13), nocistatin and prepronociceptin(154 - 181) effects on calcium channel currents and a potassium current in rat locus coeruleus in vitro.

Authors:  M Connor; C W Vaughan; E A Jennings; R G Allen; M J Christie
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

7.  NOP receptor antagonism reduces alcohol drinking in male and female rats through mechanisms involving the central amygdala and ventral tegmental area.

Authors:  Anna Maria Borruto; Yannick Fotio; Serena Stopponi; Gloria Brunori; Michele Petrella; Francesca Felicia Caputi; Patrizia Romualdi; Sanzio Candeletti; Rajesh Narendran; Linda M Rorick-Kehn; Massimo Ubaldi; Friedbert Weiss; Roberto Ciccocioppo
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

8.  Control of glutamate and GABA release by nociceptin/orphanin FQ in the rat lateral amygdala.

Authors:  S Meis; H C Pape
Journal:  J Physiol       Date:  2001-05-01       Impact factor: 5.182

9.  Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1-14)NH2.

Authors:  M Kitayama; T A Barnes; G Carra; J McDonald; G Calo; R Guerrini; D J Rowbotham; G Smith; D G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-04       Impact factor: 3.000

10.  Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone-inducible mammalian expression system.

Authors:  J McDonald; T A Barnes; H Okawa; J Williams; G Calo'; D J Rowbotham; D G Lambert
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.